These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30554986)

  • 21. Crizotinib for
    Tacar SY; Yilmaz M; Oz B; Tural D
    Tumori; 2022 Jun; 108(3):258-262. PubMed ID: 33849345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
    Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
    JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
    [No Abstract]   [Full Text] [Related]  

  • 26. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
    Miao K; Zhang X; Wang H; Si X; Zhang L
    Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.
    Miao YL; Xu QQ
    Lung Cancer; 2019 Apr; 130():84-86. PubMed ID: 30885356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Li J; Wang Y; Zhang B; Xu J; Cao S; Zhong H
    Lung Cancer; 2020 Nov; 149():17-22. PubMed ID: 32949827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
    Yang H; Zhou Z; Lin L; Yang M; Li C; Li Z; Yu X; Lizaso A; Han-Zhang H; Li B; Xiang J; Mao X; Xu Q; Zhang Y; Yang N
    Lung Cancer; 2020 Oct; 148():113-121. PubMed ID: 32889305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL
    Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With
    Hur JY; Ku BM; Shim JH; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    In Vivo; 2020; 34(3):1399-1406. PubMed ID: 32354937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
    Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
    Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma.
    Suryavanshi M; Shah A; Kumar D; Panigrahi MK; Metha A; Batra U
    Oncol Res Treat; 2017; 40(4):198-202. PubMed ID: 28324883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of crizotinib in a lung cancer patient with discordant ALK testing results.
    Grocholski S; Banerji S; Qing G; Dawe DE
    Cancer Treat Res Commun; 2018; 15():13-16. PubMed ID: 30207282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.
    Li Y; Zhang R; Zhou Y; Song J; Luo W; Tian P; Li W
    Clin Lung Cancer; 2019 May; 20(3):e251-e255. PubMed ID: 30638795
    [No Abstract]   [Full Text] [Related]  

  • 38. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
    Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
    Zhao ZM; Wang SP; Sun L; Ji YX
    Chin Med J (Engl); 2020 Nov; 134(3):373-374. PubMed ID: 33186133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.